• Twitter
  • LinkedIn
  • Home
  • About Galectin
  • Our Team
  • Our Pipeline
  • News
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
  • Contact Us
galectin-slider-v1-670x220

News

Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

June 21, 2017 | Press Release

Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial

June 13, 2017 | Press Release

Autoimmune Disease Patent Granted to Galectin Therapeutics

June 6, 2017 | Press Release
Read more

Videos

Why did you choose to become the CEO of Galectin Therapeutics?

Are you conducting clinical trials with GR-MD-02? What results have you seen so far?

Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?

Why are the results of the GR-MD-02 psoriasis study so promising?

Why is the NASH-CX trial so important?

See all videos
Galectin Therapeutics, Inc.

NASDAQ: GALT

Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.

Corporate Snapshot

  • Latest Corporate Presentation

  • Media Fact Sheet

  • Corporate Fact Sheet

Subscribe

© 2017 Galectin Therapeutics Inc. - All Rights Reserved
Privacy Policy | Terms of Use | Site Map
Disclaimer: This site may contain forward-looking information.